Tariff tensions: creating a turning point for domestic pharma manufacturing

Published: 20-Jun-2025
Distribution Finance

The pharmaceutical industry is at a critical juncture. As potential US tariffs threaten its longstanding strategy of low-cost global sourcing, companies are being forced to rethink their approach to supply chain resilience

You need to be a subscriber to read this article.
Click here to find out more.

For years, the drug manufacturing sector has leveraged global suppliers to minimise costs and ensure the availability of essential materials.

However, the prospect of new US tariffs, signalled by President Trump in April 2025, jeopardises this established approach. Tiffany Brewer (pictured), Senior Director, Global Industry Strategy—Life Sciences at Blue Yonder, reports. 

Not yet a Subscriber?

This is a small extract of the full article which is available ONLY to premium content subscribers. Click below to get premium content on Manufacturing Chemist.

Subscribe now Already a subscriber? Sign in here.
  • Companies:
  • Blue Yonder
See more

You may also like

Finance

Sanofi completes acquisition of Blueprint Medicines

Read more
Sanofi announces the completion of its acquisition of Blueprint Medicines Corporation, adding to its portfolio a commercialised medicine and the expertise of a company specialising in systemic mastocytosis (SM) and other KIT-driven diseases

Trending Articles

  1. Gerresheimer reports H1 2025 growth driven by Bormioli Pharma acquisition Cosmetics and oral liquids markets dampen organic revenue but outlook remains strong
  2. Antares Vision Group and LedgerDomain agreement will streamline DSCSA compliance and enhance system security Antares Vision Group, a leader in the digitalisation and traceability of products and supply chains for companies and institutions, announces a strategic partnership with LedgerDomain, a leader in secure digital identity and credentialing for the healthcare supply chain
  3. Strategic investment by Bain Capital, Kohlberg and Mubadala fuels PCI Pharma Services’ expansion This financial injection is expected to cement PCI’s position in the CDMO arena
  4. Samsung Biologics signs $514m manufacturing contract with US-based pharma company The six year contract manufacturing deal will provide see Samsung Biologics produce pharmaceutical products for an undisclosed, US-based company
  5. Almac completes a multi-million-pound investment enhancing cold chain capabilities in Craigavon Almac Clinical Services, part of the Almac Group, has completed a multi-million-pound investment to enhance cold chain capabilities at its global headquarters in Craigavon, Northern Ireland

Upcoming event

POWTECH

23-25 September 2025 | Exhibition | Nuremberg, Germany See all

You may also like

Finance

Sanofi completes acquisition of Blueprint Medicines

Sanofi announces the completion of its acquisition of Blueprint Medicines Corporation, adding to its portfolio a commercialised medicine and the expertise of a company specialising in systemic mastocytosis (SM) and other KIT-driven diseases
Finance

Evestia Clinical to merge with Atlantic Research Group

The merger delivers on Evestia Clinical’s strategy of targeted growth through the expansion of services, enhanced technology and broadened geographical reach
Research & Development

Amphista Therapeutics reaches research milestone and triggers a milestone payment from Merck

Collaboration focuses on the discovery of novel, non-CRBN/VHL, Targeted Glue degraders for oncology and immunology indications
Manufacturing

Gerresheimer reports H1 2025 growth driven by Bormioli Pharma acquisition

Cosmetics and oral liquids markets dampen organic revenue but outlook remains strong
Research & Development

Strategic investment by Bain Capital, Kohlberg and Mubadala fuels PCI Pharma Services’ expansion

This financial injection is expected to cement PCI’s position in the CDMO arena
Distribution

Antares Vision Group and LedgerDomain agreement will streamline DSCSA compliance and enhance system security

Antares Vision Group, a leader in the digitalisation and traceability of products and supply chains for companies and institutions, announces a strategic partnership with LedgerDomain, a leader in secure digital identity and credentialing for the healthcare supply chain
Finance

Pila Pharma bags nearly £1.5m to aid obesity drug development

The ex-Novo Nordisk researcher-founded biotech will use the money to expand its obesity clinical pipeline
Subscribe now